Mabwell initiates phase 3 clinical study of its Nectin-4 targeting ADC 9MW2821 for the treatment of TNBC

CAR-T Digest - August 2020

23 April 2026: Mabwell initiates phase 3 clinical study of its Nectin-4 targeting ADC 9MW2821 for the treatment of TNBC

Mabwell announced the initiation of a Phase 3 clinical trial for its Nectin-4 targeting ADC 9MW2821 in triple-negative breast cancer (TNBC), marking an important step forward in late-stage development
The Phase 3 study is designed to compare 9MW2821 with standard chemotherapy in patients with locally advanced or metastatic TNBC who have previously received taxane-based therapy, with or without immunotherapy, and prior ADC treatment
This development targets a high unmet need, as treatment options remain limited for patients who progress after topoisomerase inhibitor based ADCs, where chemotherapy continues to be the primary option with modest benefit
Notably, 9MW2821 is the first Nectin-4 targeting ADC to enter Phase 3 for TNBC, and this study represents its fourth pivotal trial, highlighting the drug’s growing clinical momentum across multiple tumor types
Overall, 9MW2821 continues to gain traction as a promising Nectin-4 directed ADC, with prior FDA FTD and ongoing global studies, positioning it as a potential new option in aggressive cancers like TNBC